Mental Health Study Slams Managed Care

23 September 1997

The treatment of severely mentally-ill people by managed care companiesacross the USA is "shockingly inadequate," according to a new study by the National Alliance for the Mentally Ill.

The year-long study of nine managed care plans enrolling 73 million people found that most: do not define a suicide attempt as a medical emergency or have policies that ensure immediate care; do not cover the newest treatments, especially for schizophrenia; and frequently use outdated treatment guidelines, limit coverage for inpatient hospital care and deny treatment to disruptive and noncompliant patients.

The Alliance's executive director, Laurie Flynn, said the survey shows that "cost-cutting is being done at the expense of the sickest individuals." The Alliance is calling for more public accountability for managed care plans, through public involvement and outcomes measures, and for managed care companies to improve treatment guidelines. It says Congress should examine the plans' handling of people with severe mental illnesses in Medicaid programs, with the aim of producing consumer protection legislation; this could also be passed at state level. The states should also monitor the performance of managed care plans, it says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight